Financial Survey: ObsEva (NASDAQ:OBSV) and Trevena (NASDAQ:TRVN)

ObsEva (NASDAQ:OBSV) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations and institutional ownership.

Profitability

This table compares ObsEva and Trevena’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ObsEva	N/A	-416.36%	-92.01%
Trevena	N/A	N/A	-119.55%

Volatility & Risk

ObsEva has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Comparatively, Trevena has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for ObsEva and Trevena, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ObsEva	0	0	0	0	0.00
Trevena	0	1	0	0	2.00

Trevena has a consensus price target of $5.00, suggesting a potential upside of 41,566.67%. Given Trevena’s stronger consensus rating and higher probable upside, analysts plainly believe Trevena is more favorable than ObsEva.

Institutional and Insider Ownership

17.5% of ObsEva shares are owned by institutional investors. Comparatively, 13.6% of Trevena shares are owned by institutional investors. 14.4% of ObsEva shares are owned by insiders. Comparatively, 2.7% of Trevena shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares ObsEva and Trevena”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ObsEva	N/A	N/A	-$58.38 million	($0.92)	N/A
Trevena	$443,000.00	0.03	-$40.29 million	($47.04)	0.00

Trevena has higher revenue and earnings than ObsEva. Trevena is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Summary

Trevena beats ObsEva on 6 of the 11 factors compared between the two stocks.

About ObsEva

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

About Trevena

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.